SR9009 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-06-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
=== Ligand gated ion channel inverse agonists === An example of a receptor site that possesses basal activity and for which inverse agonists have been identified is the GABAA receptors. Agonists for GABAA receptors (such as muscimol) create a relaxant effect, whereas inverse agonists have agitation effects (for example, Ro15-4513) or even convulsive and anxiogenic effects (certain beta-carbolines).
The largest man-made sources of carbonyl sulfide release include its primary use as a chemical intermediate and as a byproduct of carbon disulfide production; however, it is also released from automobiles and their tire wear, coal-fired power plants, coking ovens, biomass combustion, fish processing, combustion of refuse and plastics, petroleum manufacture, and manufacture of synthetic fibers, starch, and rubber. The average total worldwide release of carbonyl sulfide to the atmosphere has been estimated at about 3 million tons per year, of which less than one third was related to human activity. It is also a significant sulfur-containing impurity in many fuel gases such as synthesis gas, which are produced from sulfur-containing feedstocks. Carbonyl sulfide is present in foodstuffs, such as cheese and prepared vegetables of the cabbage family. Traces of COS are naturally present in grains and seeds in the range of 0.05–0.1 mg/kg. Carbonyl sulfide has been observed in the interstellar medium (see also List of molecules in interstellar space), in comet 67P and in the atmosphere of Venus, where, because of the difficulty of producing COS inorganically, it is considered a possible indicator of life.
=== Church Decorations === Order of Saint Sava, 1st class (Serbian Orthodox Church) Order of Saint Bishop Nicholas of Serbia (Diocese of Sabac, Serbian Orthodox Church) Order of Saint Prince Lazar (Diocese of Raska and Prizren, Serbian Orthodox Church) Grand Cross of the Order of the Holy Sepulchre (Orthodox) (Patriarchate of Jerusalem)
Sources: en.wikipedia.org
==== MeSH D06.472.351 – gonadotropins ==== MeSH D06.472.351.326 – chorionic gonadotropin MeSH D06.472.351.326.125 – chorionic gonadotropin, beta subunit, human MeSH D06.472.351.326.562 – glycoprotein hormones, alpha subunit MeSH D06.472.351.451 – gonadotropins, equine MeSH D06.472.351.576 – gonadotropins, pituitary MeSH D06.472.351.576.288 – follicle stimulating hormone MeSH D06.472.351.576.288.500 – follicle stimulating hormone, beta subunit MeSH D06.472.351.576.288.750 – glycoprotein hormones, alpha subunit MeSH D06.472.351.576.463 – luteinizing hormone MeSH D06.472.351.576.463.249 – glycoprotein hormones, alpha subunit MeSH D06.472.351.576.463.500 – luteinizing hormone, beta subunit MeSH D06.472.351.576.583 – menotropins MeSH D06.472.351.576.583.500 – urofollitropin MeSH D06.472.351.576.773 – prolactin
=== United States === According to the US Food and Drug Administration (FDA), an orphan drug is defined as one "intended for the treatment, prevention or diagnosis of a rare disease or condition, which is one that affects less than 200,000 persons in the US" (which equates to approximately 6 cases per 10,000 population) "or meets cost recovery provisions of the act".
== Modeling == Models have been developed to simplify conceptualization of the many processes that take place in the interaction between an organism and a chemical substance. Pharmacokinetic modelling may be performed either by noncompartmental or compartmental methods. Multi-compartment models provide the best approximations to reality; however, the complexity involved in adding parameters with that modelling approach means that monocompartmental models and above all two compartmental models are the most-frequently used. The model outputs for a drug can be used in industry (for example, in calculating bioequivalence when designing generic drugs) or in the clinical application of pharmacokinetic concepts. Clinical pharmacokinetics provides many performance guidelines for effective and efficient use of drugs for human-health professionals and in veterinary medicine. Models generally take the form of mathematical formulas that have a corresponding graphical representation. The use of these models allows an understanding of the characteristics of a molecule, as well as how a particular drug will behave given information regarding some of its basic characteristics such as its acid dissociation constant (pKa), bioavailability and solubility, absorption capacity and distribution in the organism. A variety of analysis techniques may be used to develop models, such as nonlinear regression or curve stripping.
== External links == FDA regulation on the use of TTI's in the seafood industry. Article on the introduction of a TTI at a large food producer Archived 2018-08-14 at the Wayback Machine WRAP Food Waste Report (1.4 MB) WHO Factsheet on the global amount of food related illnesses Article on the introduction of a TTI at a food producer in Switzerland
Sources: en.wikipedia.org
The Ayrshire and Simmental breeds were imported first, followed by the Brown Swiss, but few people wanted to crossbreed with them because of their large size, and the Japanese government encouraged it, but the crossbreds were very unpopular. The crossbreds' oversized stature made them inconvenient for Japan's narrow arable land, and their movements were slow and sluggish, and their temperaments were rough and lacking in obedience. They also had poor meat quality and were condemned from all quarters as being unsuitable for sukiyaki. As a result, from around 1907, there were no more crossbreds being bred, and in reaction, the old black cattle were considered good, and as long as they were small and black, they could be sold. As crossbreeding with Western breeds progressed, the term "pure Wagyu" (純粋和牛, junsui Wagyū) emerged to describe native Japanese cattle, and by 1912, it was claimed that there were two definitions of Wagyu: "pure Wagyu" and "improved Wagyu" (改良和牛, kairyō Wagyū). At that time, Mendel's laws had just been rediscovered, and both the Japanese government and cattle farmers lacked sufficient knowledge of genetics. The unpopularity of crossbred cattle led to the Japanese government's decision in 1911 to suspend plans to purchase Brown Swiss and Simmental cattle. In 1912, the Japanese government decided to formally end its policy of encouraging crossbreeding by announcing that crossbreeding between Wagyu and European breeds had been sufficiently successful. From then on, Wagyu improvement was based on pure Wagyu and improved Wagyu (crossbred cattle).
=== Cultural aspects of exhumation === Frequently, cultures have different sets of exhumation taboos. Occasionally these differences result in conflict, especially in cases where a culture with more lenient exhumation rules wishes to operate on the territory of a different culture. For example, U.S. construction companies have run into conflict with Native American groups that have wanted to preserve their burial grounds from disturbance. In Southern Chinese culture, graves are opened after a period of years. The bones are removed, cleaned, dried, and placed in a ceramic pot for reburial (in Taiwan), or in a smaller coffin and to be reburied in another location (in Vietnam). The practice is called jiǎngǔ(撿骨) in Taiwan, or Bốc mộ(卜墓) in Vietnam "digging up bones" and is an important ritual in the posthumous "care" of children for their deceased parents and ancestors. Jewish law forbids the exhumation of a corpse. The majority of Muslim jurors maintain that an individual buried in a mosque must be exhumed and that offering prayers in such a mosque renders the prayer invalid. Jurists, however, hold that mosques built around already existing graves are to be demolished. In England and Wales once the top of a coffin has been lowered below ground level during a burial, raising the coffin again, for any reason, is considered exhumation regardless of the cause. Even if further work is necessary to properly fit the casket into the grave without further, the Home Office must to be notified and a full investigation undertaken.
== History == The first Outback Steakhouse location was opened on March 15, 1988, in Tampa, Florida. Canadian Outback Steakhouse restaurants began in 1996. In March 2009, Outback Steakhouse Canada abruptly closed all nine locations in the province of Ontario, citing poor economic conditions, but in June 2009, Outback Steakhouse opened a location in Niagara Falls, Ontario, with a second location later opening in the same city. As of 2024, these are the only Outback Steakhouse locations operating in Canada. Outback locations in Hawaii began to open in the mid 1990s, as part of a massive expansion across the country. On February 17, 2024, Outback’s parent company, Bloomin’ Brands, announced the permanent closure of all remaining Hawaii locations, as part of financial restructuring, citing a significant decrease in profits. This was part of a larger, mass closure of over 41 locations. All three locations in Hawaii were permanently closed by February 18, 2024. Outback Steakhouse opened in the UK with locations in Birmingham, Basildon, Enfield, Romford, Stevenage, Wandsworth in London and Staines. By September 2011, only its Basildon and Romford stores remained and they closed down on September 13, ending Outback's foray into the UK market. In 2006, a new Outback logo was introduced, dropping the old kangaroo logo for a more simplistic and modern Outback mountain range logo.
=== 19S regulatory particle === The 19S particle in eukaryotes consists of 19 individual proteins and is divisible into two subassemblies, a 9-subunit base that binds directly to the α ring of the 20S core particle, and a 10-subunit lid. Six of the nine base proteins are ATPase subunits from the AAA Family, and an evolutionary homolog of these ATPases exists in archaea, called PAN (proteasome-activating nucleotidase). The association of the 19S and 20S particles requires the binding of ATP to the 19S ATPase subunits, and ATP hydrolysis is required for the assembled complex to degrade folded and ubiquitinated proteins. Note that only the step of substrate unfolding requires energy from ATP hydrolysis, while ATP-binding alone can support all the other steps required for protein degradation (e.g., complex assembly, gate opening, translocation, and proteolysis). In fact, ATP binding to the ATPases by itself supports the rapid degradation of unfolded proteins. However, while ATP hydrolysis is required for unfolding only, it is not yet clear whether this energy may be used in the coupling of some of these steps.
=== Health care === In 2019, Pritzker approved a tax on private insurance to help fund the state's Medicaid program. In August of that year, he signed legislation to eliminate the state's backlog of Medicaid applications, which as of March 15, 2019, included 112,000 that remained unprocessed past the federal 45-day limit. According to data from the Illinois Department of Human Services, the backlog was eliminated as of June 2020. In August 2023, under provisions of Illinois House Bill 2189 (the Access to Afford Insulin Act), Pritzker signed legislation capping insurance holders' out-of-pocket price of insulin at $35 for a 30-day supply. In July 2024, Pritzker signed bills allowing Illinois to spend $10 million to purchase medical debt from creditors, known as the Medical Debt Relief Pilot Program, under the Illinois Department of Healthcare and Family Services. The program was created to eliminate nearly $1 billion in medical debt for 340,000 low-income state residents. In February 2025, Pritzker announced that approximately 270,000 Illinoisans' medical debt, totaling $345 million, had been erased under the program. On April 22, 2025, United States Secretary of Health and Human Services Robert F. Kennedy Jr. announced a plan to use government data to help determine the causes of autism. In response, Pritzker signed an executive order that made Illinois the first state to block the federal government from collecting personal health data related to autism. In 2025, Pritzker signed Illinois House Bill 1697, the Prescription Drug Affordability Act.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.